BioNexus Gene Lab Corp. Operating Cash Flow
BioNexus Gene Lab Corp. (BGLC) reported Operating Cash Flow of -$570.16 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$422.49K.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$147.67K.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $961.06K, a 338.43% increase year-over-year.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.24M.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for fiscal 2025 was -$1.84M.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for fiscal 2024 was -$2.09M.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for fiscal 2023 was -$1.82M, a 430.22% decline from fiscal 2022.
- BioNexus Gene Lab Corp. net cash provided by (used in) operating activities for fiscal 2022 was $551.82K, a 5923.60% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$422.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$570.16K 10-Q · filed 2026-08-14 | $390.90K derived: sum of 3 quarters · filed 2026-08-14 | -$846.57K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | -$147.67K 10-Q · filed 2026-05-15 | $813.39K derived: sum of 2 quarters · filed 2026-05-15 | -$424.07K derived: sum of 3 quarters · filed 2026-05-15 | -$1.16M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $961.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$276.40K derived: sum of 2 quarters · filed 2026-04-14 | -$1.01M derived: sum of 3 quarters · filed 2026-08-14 | -$1.84M 10-K · filed 2026-04-14 | ||||
| 2025-09-30 | -$1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.98M derived: sum of 2 quarters · filed 2026-08-14 | -$2.80M 10-Q · filed 2025-11-14 | -$2.58M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | -$737.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.56M 10-Q · filed 2026-08-14 | -$1.34M derived: sum of 3 quarters · filed 2026-08-14 | -$2.95M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | -$824.07K 10-Q · filed 2026-05-15 | -$604.87K derived: sum of 2 quarters · filed 2026-05-15 | -$2.21M derived: sum of 3 quarters · filed 2026-05-15 | -$2.88M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $219.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$1.38M derived: sum of 2 quarters · filed 2026-04-14 | -$2.06M derived: sum of 3 quarters · filed 2026-04-14 | -$2.09M 10-K · filed 2026-04-14 | -$2.23M 10-K · filed 2025-04-15 | |||
| 2024-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$2.28M derived: sum of 2 quarters · filed 2025-11-14 | -$2.31M 10-Q · filed 2025-11-14 | -$2.16M 10-Q · filed 2024-11-15 | -$3.09M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | -$672.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$709.43K 10-Q · filed 2025-08-18 | -$704.98K 10-Q · filed 2024-08-14 | -$1.49M derived: sum of 3 quarters · filed 2025-08-18 | -$2.39M derived: sum of 4 quarters · filed 2025-08-18 | |||
| 2024-03-31 | -$37.15K 10-Q · filed 2025-05-15 | -$34.44K 10-Q · filed 2024-05-15 | -$819.68K derived: sum of 2 quarters · filed 2025-05-15 | -$1.72M derived: sum of 3 quarters · filed 2025-05-15 | -$1.74M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$782.53K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$1.68M derived: sum of 2 quarters · filed 2025-04-15 | -$1.71M derived: sum of 3 quarters · filed 2025-04-15 | -$1.82M 10-K · filed 2025-04-15 | -$1.30M 10-K · filed 2024-04-16 | |||
| 2023-09-30 | -$899.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | -$923.17K derived: sum of 2 quarters · filed 2024-11-15 | -$1.04M 10-Q · filed 2024-11-15 | -$562.95K derived: sum of 4 quarters · filed 2024-11-15 | ||||
| 2023-06-30 | -$23.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$140.34K 10-Q · filed 2024-08-14 | $336.40K derived: sum of 3 quarters · filed 2024-08-14 | $645.29K derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$116.52K 10-Q · filed 2024-05-15 | -$118.30K 10-Q · filed 2023-05-09 | $360.22K derived: sum of 2 quarters · filed 2024-05-15 | $669.11K derived: sum of 3 quarters · filed 2024-05-15 | $473.14K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $476.74K derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-04-16 | $785.63K derived: sum of 2 quarters · filed 2024-04-16 | $589.66K derived: sum of 3 quarters · filed 2024-04-16 | $551.82K 10-K · filed 2024-04-16 | $544.03K 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $308.89K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-03-26 | $112.92K derived: sum of 2 quarters · filed 2024-03-26 | $75.08K 10-Q/A · filed 2024-03-26 | $69.56K 10-Q · filed 2022-11-14 | $558.09K derived: sum of 4 quarters · filed 2024-03-26 | |||
| 2022-06-30 | -$195.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-16 | -$233.81K 10-Q · filed 2023-08-16 | -$237.59K 10-Q · filed 2022-08-15 | $249.20K derived: sum of 3 quarters · filed 2023-08-16 | $565.07K derived: sum of 4 quarters · filed 2023-08-16 | |||
| 2022-03-31 | -$37.84K 10-Q · filed 2023-05-09 | $445.17K derived: sum of 2 quarters · filed 2023-05-09 | $761.04K derived: sum of 3 quarters · filed 2023-05-09 | -$144.11K derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $483.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $798.88K derived: sum of 2 quarters · filed 2023-03-31 | -$106.27K derived: sum of 3 quarters · filed 2023-03-31 | $9.16K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $315.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$589.27K derived: sum of 2 quarters · filed 2022-11-14 | -$473.85K 10-Q · filed 2022-11-14 | $458.64K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$905.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$789.72K 10-Q · filed 2022-08-15 | -$819.89K 10-Q · filed 2021-08-12 | $142.77K derived: sum of 3 quarters · filed 2022-08-15 | $897.51K derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $115.43K 10-Q · filed 2022-05-16 | $1.05M derived: sum of 2 quarters · filed 2022-05-16 | $1.80M derived: sum of 3 quarters · filed 2022-05-16 | $1.65M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $932.48K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | $1.69M derived: sum of 2 quarters · filed 2022-04-06 | $1.53M derived: sum of 3 quarters · filed 2022-04-06 | $552.68K 10-K · filed 2022-04-06 | ||||
| 2020-09-30 | $754.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $597.55K derived: sum of 2 quarters · filed 2021-11-15 | -$379.80K 10-Q · filed 2021-11-15 | -$154.91K 10-Q · filed 2020-11-03 | -$438.16K derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | -$157.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.13M 10-Q · filed 2021-08-12 | -$97.94K 10-Q · filed 2020-08-11 | -$1.19M derived: sum of 3 quarters · filed 2021-08-12 | -$1.25M derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$977.35K 10-Q · filed 2021-05-18 | -$40.59K 10-Q · filed 2020-05-08 | -$1.04M derived: sum of 2 quarters · filed 2021-05-18 | -$1.09M derived: sum of 3 quarters · filed 2021-05-18 | -$1.15M derived: sum of 4 quarters · filed 2021-05-18 | |||
| 2019-12-31 | -$58.36K derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-03-30 | -$115.78K derived: sum of 2 quarters · filed 2021-03-30 | -$168.71K derived: sum of 3 quarters · filed 2021-03-30 | -$217.27K 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | -$57.41K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2020-11-09 | -$110.35K derived: sum of 2 quarters · filed 2020-11-09 | -$158.91K 10-Q/A · filed 2020-11-09 | $84.88K derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | -$52.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$101.50K 10-Q · filed 2020-08-11 | $142.29K derived: sum of 3 quarters · filed 2020-08-11 | $318.82K derived: sum of 4 quarters · filed 2020-08-11 | ||||
| 2019-03-31 | -$48.56K 10-Q · filed 2020-05-08 | $195.23K derived: sum of 2 quarters · filed 2020-05-08 | $371.75K derived: sum of 3 quarters · filed 2020-05-08 | $350.92K derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | $243.79K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | $420.31K derived: sum of 2 quarters · filed 2020-03-31 | $399.48K derived: sum of 3 quarters · filed 2020-03-31 | -$274.08K 10-K · filed 2020-03-31 | ||||
| 2018-09-30 | $176.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $155.69K derived: sum of 2 quarters · filed 2019-11-14 | -$517.87K 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | -$20.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$694.39K 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | -$673.56K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |